18 F-Flutemetamol PET/CT for Transthyretin Amyloid Cardiomyopathy : Timing Matters

Eun Ji Han; Yeoun Eun Sung; Mi-Hyang Jung; Joo Hyun O; Jong-Chan Youn

doi:10.1097/RLU.0000000000004411

18 F-Flutemetamol PET/CT for Transthyretin Amyloid Cardiomyopathy : Timing Matters

Clin Nucl Med. 2022 Dec 1;47(12):1074-1076. doi: 10.1097/RLU.0000000000004411. Epub 2022 Oct 14.

Authors

Eun Ji Han¹, Yeoun Eun Sung², Mi-Hyang Jung³, Joo Hyun O⁴, Jong-Chan Youn³

Affiliations

¹ From the Division of Nuclear Medicine, Department of Radiology, Yeouido St Mary's Hospital, College of Medicine.
² Department of Hospital Pathology, Seoul St Mary's Hospital, College of Medicine.
³ Division of Cardiology, Department of Internal Medicine, Seoul St Mary's Hospital, Catholic Research Institute for Intractable Cardiovascular Disease, College of Medicine.
⁴ Division of Nuclear Medicine, Department of Radiology, Seoul St Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.

PMID: 36240762
DOI: 10.1097/RLU.0000000000004411

Abstract

We report 18 F-flutemetamol PET/CT finding in an 88-year-old man with cognitive impairment and transthyretin amyloid cardiomyopathy. Early phase PET/CT images showed significantly increased myocardial uptake, but there was no myocardial uptake in delayed phase PET/CT images. A dual-time-point amyloid PET/CT imaging may be helpful to diagnose and differentiate subtypes of amyloid cardiomyopathy in patients with suspected cardiac amyloidosis.

Publication types

Case Reports

MeSH terms

Aged, 80 and over
Amyloid
Amyloidosis*
Aniline Compounds
Benzothiazoles
Cardiomyopathies* / diagnostic imaging
Humans
Male
Positron Emission Tomography Computed Tomography
Positron-Emission Tomography
Prealbumin

Substances

flutemetamol
Prealbumin
Aniline Compounds
Benzothiazoles
Amyloid